News

The Phase I/II study (STELLAR-001) will evaluate the safety and efficacy of durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in combination with Innate's investigational first-in-class anti-C5aR monoclonal antibody, IPH5401,

The study, led by Dr. Tim Greten at the National Cancer Institute (NCI), is being conducted as part of a Cooperative Research and Development Agreement (CRADA) with the

Sanofi has offered €45 for each of the shares of Ablynx in an all-cash deal. The acquisition will help Sanofi advance the transformation of its research and development

The company has announced the top-line results from the Phase III KRONOS trial, which showed PT010 (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6µg, using Aerosphere Delivery Technology, in a pressurised metered-dose inhaler

Concept represents a new, high-growth area for Spectris, and will become a separate operating company within its Materials Analysis segment where it has strong synergies with the activities

GEP-NET is a form of cancer that affects the pancreas or gastrointestinal tract. The approval is for adult patients with somatostatin receptor-positive GEP-NETs and it covers conditions like foregut, midgut,

REX-001 has been shown to trigger the growth of new blood vessels to replenish blood supply to the limb, reduce symptoms and boost quality of life of patients

This designation is for treating patients diagnosed with HER2-positive metastatic breast cancer (MBC) that has progressed during or after at least two HER2-targeting treatment regimens for locally advanced

The study is expected to commence in the second half of 2018. The upcoming clinical phase I study with ATOR-1015 is a first-in-human dose escalation study in patients